INTRODUCTION
============

Lobectomy with systematic mediastinal lymph node dissection has played the most important role in the treatment of patients with stage I non-small cell lung cancer (NSCLC).^[@ref1])^ With regard to pulmonary function, the predicted postoperative (ppo) pulmonary function values have been reported to be more strongly related to operative morbidity, mortality, and survival than the preoperative values.^[@ref2]-[@ref5])^ Current evidence suggests that a ppo-forced expiratory volume in the first second (FEV~1~) of \< 30% and/or a ppo-diffusing capacity of the lung for carbon monoxide (DL~CO~) of \< 30% are high-risk factors (and contraindications) for major anatomical lung resection for lung cancer from the point of view of postoperative morbidity and mortality.^[@ref2],\ [@ref3])^ In the American College of Chest Physicians (ACCP) guideline, patients with either a ppo-FEV~1~ or ppo-DL~CO~ of \< 60% and in whom both values are ≥ 30%, are recommended to undergo further exercise tests as a preoperative assessment.^[@ref2])^ Historically, however, 'marginal-risk' patients with a ppo-FEV~1~ and/or a ppo-DL~CO~ of 30--60% have not received much attention. Moreover, only a few studies have reported the long-term prognostic significance of the ppo-pulmonary function values.^[@ref4],\ [@ref5])^

Based on the circumstances indicated above, we hypothesized that 'marginal-risk' patients with a ppo-FEV~1~ and/or a ppo-DL~CO~ of 30--60% are a subgroup of patients with poor short- and long-term postoperative outcomes. The present study was designed to elucidate the significance of the 'marginal-risk' status in those outcomes of a cohort of patients with suspected clinical stage I NSCLC and, consequently, to help establish better management procedures for patients with suspected lung nodules.

METHODS
=======

The study was conducted with the approval of the Institutional Review Board of Nagoya University Hospital. We reviewed the medical records of 426 consecutive patients who underwent anatomical complete resection for clinical stage I NSCLC at Nagoya University Hospital between April 2008 and December 2012. Patients with concomitant cancer resection of the lung and other organs (n = 2), concomitant cardiovascular surgery (n = 2), or incomplete pulmonary function test data (n = 6) were excluded from the analysis. Twenty-five patients with nonsolid nodules were also excluded. After applying the exclusion criteria, 391 patients were included in the study population. Seventy-three patients were classified as 'marginal-risk' (ppo-FEV~1~: 30--60% and/or ppo-DL~CO~: 30--60%); 318 patients were classified as 'normal-risk' (ppo-FEV~1~ ≥ 60% and ppo-DL~CO~ ≥ 60%).

Ppo-FEV~1~ and ppo-DL~CO~ were defined as follows:

ppo-FEV~1~ (%) = measured FEV~1~ (%) × (1 -- the number of segments resected / the number of functional segments).

ppo-DL~CO~ (%) = measured DL~CO~ (%) × (1 -- the number of segments resected / the number of functional segments).

Segmentectomy was performed instead of lobectomy in selected patients who had previously undergone pulmonary resection and patients with another major comorbidity, peripheral nodules ≤ 2 cm in diameter, limited pulmonary function, or lower exercise tolerance. The 7th edition of the tumor-node-metastasis classification was applied in this cohort, and the pathological diagnosis of the tumor was made based on the World Health Organization classification.^[@ref6],\ [@ref7])^

STATISTICAL ANALYSIS
====================

The chi-square and Wilcoxon tests were used for the comparisons of proportions and continuous values, respectively. Postoperative morbidity was defined as the occurrence of at least one postoperative event based on The Society of Thoracic Surgeons and the European Society of Thoracic Surgeons general thoracic surgery databases.^[@ref8])^ Prolonged hospital stay was defined as hospitalization for more than 14 days after surgery. Overall survival (OS) was defined as the time from surgery to death due to any cause. A multivariate logistic regression analysis was performed to estimate the odds ratios (ORs) and 95% confidence intervals (CIs) for postoperative morbidity and a prolonged hospital stay. The Kaplan--Meier method was used to estimate OS, and the log-rank test was used to compare the survival curves. A multivariate Cox regression analysis was performed to estimate the hazard ratios (HRs) and 95% CIs for OS. Statistical significance was defined as p \< 0.05. All analyses were conducted using the JMP software program (version 11.0.0, SAS institute Inc., Cary, NC).

RESULTS
=======

In the preoperative setting, 283 ('marginal-risk' \[84%\]; 'normal-risk' \[70%\]) patients underwent a lung biopsy, which led to a definitive diagnosis in 194 patients ('marginal-risk' \[63%\]; 'normal-risk' \[47%\]). [Table 1](#table1){ref-type="table"} shows the clinicopathological characteristics of 73 'marginal-risk' patients and 318 'normal-risk' patients. The 'marginal-risk' patient subgroup was characterized by a greater proportion of males, a higher number of current or former smokers, a greater proportion of pathological N1/2 disease, and a higher rate of thoracotomy.

###### 

The characteristics of patients stratified by the predicted postoperative pulmonary function values

                                                   'Marginal-risk' (n = 73)   'Normal-risk' (n = 318)   P value
  ---------------------------- ------------------- -------------------------- ------------------------- ----------
  ppo-FEV~1~, % of predicted   (Mean ± SD)         63.0 ± 16.6                88.6 ± 17.0               \< 0.001
  ppo-DL~CO~, % of predicted   (Mean ± SD)         67.2 ± 22.3                95.2 ± 20.3               \< 0.001
  Age, years                   (Mean ± SD)         69.7 ± 5.8                 68.1 ± 8.6                0.143
  Sex                          Female              12                         127                       \< 0.001
                               Male                61                         191                       
  Smoking status               Never               10                         117                       \< 0.001
                               Current or former   63                         201                       
  Nodule size, cm              (mean ± SD)         2.71 ± 0.82                2.55 ± 0.96               0.090
  Pathological N status        N0                  59                         286                       0.039
                               N1/2                14                         32                        
  Surgical procedure           Segmentectomy       6                          48                        0.105
                               Lobectomy           67                         270                       
  Surgical approach            Thoracotomy         72                         290                       0.010
                               VATS                1                          28                        
  Lymph node dissection        Sampling            8                          34                        0.947
                               Systematic          65                         284                       
  Postoperative morbidity      No                  38                         252                       \< 0.001
                               Yes                 35                         66                        
  Prolonged hospital stay      No                  56                         298                       \< 0.001
                               Yes                 17                         20                        
  Cause of death               Lung cancer         12                         17                        0.428
                               Pulmonary event     3                          4                         
                               Others              2                          8                         
                               Total               17                         29                        

SD, standard deviation; ppo, predicted postoperative; FEV~1~, forced expiratory volume in the first second; DL~CO~, diffusing capacity of the lung for carbon monoxide; VATS, video-assisted thoracic surgery.

Postoperative morbidity occurred in 35 (48%) 'marginal-risk' patients and 66 (21%) 'normal-risk' patients. Pulmonary complications occurred in 25 (34%) 'marginal-risk' patients and 35 (11%) 'normal-risk' patients. Prolonged hospital stay was required in 17 (23%) 'marginal-risk' patients and 20 (6%) 'normal-risk' patients. There were no cases of 30-day postoperative mortality. After adjusting age, sex, smoking status, nodule size, surgical procedure, surgical approach, lymph node dissection, the 'marginal-risk' status was a significant predictor of both postoperative morbidity (OR: 2.97; 95%CI: 1.71--5.18; p \< 0.001) and a prolonged hospital stay (OR: 3.83; 95%CI: 1.81--8.07; p \< 0.001).

There were no patients with a ppo-FEV~1~ and/or a ppo-DL~CO~ of \< 30%. In 6 patients with a ppo-FEV~1~ and/or a ppo-DL~CO~ of \< 40%, postoperative morbidity occurred in 5 (83%), pulmonary complications occurred in 5 (83%), prolonged hospital stay was required in 1 (17%). In 27 patients with a ppo-FEV~1~ and/or a ppo-DL~CO~ of \< 50%, postoperative morbidity occurred in 12 (44%), pulmonary complications occurred in 9 (33%), prolonged hospital stay was required in 6 (22%).

The median follow-up period was 38 months. The OS of 'marginal-risk' patients was significantly shorter than that of 'normal-risk' patients (three-year OS: 79% vs. 93%; the five-year OS: 64% vs. 87%; p \< 0.001) ([Figure 1A](#fig1a){ref-type="fig"}). Similarly, in 324 patients with pathological stage I NSCLC, the OS of 'marginal-risk' patients was also shorter in comparison to 'normal-risk' patients (p = 0.001) ([Figure 1B](#fig1b){ref-type="fig"}).
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In the multivariate Cox regression analysis, 'marginal-risk' had a prognostic value for OS ([Table 2](#table2){ref-type="table"}, analysis 1). The results of a multivariate Cox regression analysis in which the ppo-FEV~1~ and ppo-DL~CO~ were used as continuous variables instead of the 'marginal-risk' and 'normal-risk' groups are shown in Table 2, analysis 2. The ppo-DL~CO~ was a statistically significant prognostic factor for OS.

Forty-six patients died during the study period. There were no significant differences in the causes of death between the two groups ([Table 1](#table1){ref-type="table"}). The cancer-specific survival of 'marginal-risk' patients was also shorter in comparison to 'normal-risk' patients (p \< 0.001).

DISCUSSION
==========

We used ppo-FEV~1~ and DL~CO~ cut-off values of 30% and 60%, respectively, to evaluate surgical risks. These values are proposed in the ACCP guidelines.^[@ref2])^ Historically, the lower threshold of those values for curative lung resection has been the main focus of discussion. Several recent studies have demonstrated acceptable postoperative outcome in patients with a ppo-pulmonary function of \> 30% with an evaluation of ppo-oxygen consumption and a low technology exercise test.^[@ref2],\ [@ref3])^ The upper threshold of a ppo value of 60% has not received much attention. In our study of patients with clinical stage I lung cancer, 'marginal-risk' patients (defined by ppo-values of 30--60%) had significantly poorer short-and long-term postoperative outcomes.

As we previously reported, we agree that 'normal-risk' patients in whom an unverified highly suspected lung nodule is identified by diagnostic imaging can be surgically diagnosed.^[@ref9])^ However, in 'marginal-risk' patients with an unverified suspected nodule, it is preferable that a non-surgical definitive diagnosis be obtained before surgery. As for pulmonary function, only a few studies have reported the prognostic significance of ppo-pulmonary function values for predicting OS. In one retrospective study, which included patients with all-stage NSCLC, Ferguson *et al*. reported that postoperative pulmonary function was a better predictor of long-term survival after lung cancer surgery than preoperative pulmonary function.^[@ref4])^ Berry *et al*. reported that in patients with pathological stage I NSCLC OS after lobectomy was impacted not by ppo-FEV~1~ but by lower ppo-DL~CO~.^[@ref5])^ The two published studies did not include patients who underwent segmentectomy. In our study, ppo-DL~CO~ (as continuous variables) was an independent prognostic factor for OS after surgical resection ([Table 2](#table2){ref-type="table"}, analysis 2). Table 2The results of the multivariate Cox regression analysis for overall survivalAnalysis 1Analysis 2HR95%CIP valueHR95%CIP valueGroup'Normal-risk'1.00'Marginal-risk'2.071.093.830.028ppo-FEV~1~(10% decrease)1.181.001.400.050ppo-DL~CO~(10% decrease)1.161.021.330.027Age(10-year increase)1.450.982.190.0651.591.072.430.023SexFemale1.001.00Male2.031.004.550.0501.990.974.520.062Nodule size(1-cm increase)1.381.001.880.0471.391.011.920.045Pathological N statusN01.001.00N1/22.351.104.630.0282.131.014.170.047[^2]

The cancer specific survival of 'marginal-risk' patients was shorter in comparison to 'normal-risk' patients. The differences in the OS may also come from the difference in the aggressiveness of the cancer.

The present study is associated with some limitations; specifically, the study population was relatively small and the follow-up period was relatively short. Moreover, because the selection criteria of segmentectomy were highly dependent on the decisions of individual surgeons, we could not establish new valid criteria to determine the appropriate extent of surgical resection in patients with marginal ppo-pulmonary function values from this retrospective study.

In conclusion, patients who are classified as 'marginal-risk' based on ppo-pulmonary function values are a subgroup of patients with poor short-and long-term outcomes after surgery for clinical stage I NSCLC. Surgeons should take into account not only morbidity and local recurrence, but also long-term mortality.
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